Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata

    April 2023 in “ International Journal of Research in Dermatology ”
    Sultan Daghafak Alenazi, Mutaib A. Altamimi
    Studysummary The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ijord.com →
    Discuss this study in the Community →

    Related research 9

    1. Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata International Journal of Research in Dermatology · 2023
    2. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal? Frontiers in Immunology · 2022
    3. A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
    4. Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata Dermatology Reports · 2022
    5. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    6. Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2019
    7. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    8. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    9. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017